Skip to content

Ligand Pharmaceuticals LGND Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$13.35M-130%$44.78M-61.8%$117.27M+2,319%$4.85M+111%-$42.45M-36.6%
$8.22M0.0%$8.21M-0.7%$8.27M-3.0%$8.52M-2.8%$8.77M+1.7%
$10.6M-25.7%$14.27M-3.2%$14.75M+47.5%$10M+27.6%$7.84M+4.1%
$48.69M+6.0%$45.92M+251%$13.09M-17.1%$15.8M+162%-$25.45M-189%
$228K+2,433%$9K-40.0%$15K-93.0%$214K0.0%$214K-69.9%
-$94.35M-421%-$18.1M+94.9%-$353.45M-3,213%-$10.67M-318%$4.89M+113%
-$14.13M-270%$8.33M-98.0%$409.65M+2,632%$15M+416%-$4.75M-123%
-$59.83M-268%$35.55M-50.4%$71.71M+264%$19.68M+181%-$24.32M-380%
$48.46M+5.6%$45.91M+251%$13.08M-16.1%$15.59M+161%-$25.66M-192%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ligand Pharmaceuticals's cash flow data come from?
Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.